Guí a OncoSur de me l anoma 92 > 15. Weber J, DÁngelo S, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-laber, phase 3 trial. Lancet Oncol 2015;16:375-84. 16. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372(26):2521-32. 17. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (Keynote-006): post-hoc 5 years results from an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1239-51. 18. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated Melanoma. N Engl J Med 2015;372:2006-17. 19. Larkin J, Chiarion-Sileni, González R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23-34. 20. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017;5;377(14):1345-56. 21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535-46. 22. Kohlapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogenela herparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res 2016;1;22(5):1048-54.
RkJQdWJsaXNoZXIy OTI4NTYw